

Amy S Ruppert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2209064/publications.pdf>

Version: 2024-02-01

63
papers

2,998
citations

331259

21
h-index

174990

52
g-index

63
all docs

63
docs citations

63
times ranked

4146
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	13.9	706
2	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	3.4	498
3	DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2016, 48, 253-264.	9.4	254
4	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood</i> , 2014, 123, 1810-1817.	0.6	246
5	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). <i>Blood</i> , 2014, 123, 1207-1213.	0.6	176
6	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. <i>Blood</i> , 2020, 135, 2041-2048.	0.6	158
7	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. <i>Journal of Clinical Oncology</i> , 2011, 29, 1349-1355.	0.8	124
8	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748.	2.5	123
9	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	0.8	71
10	TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2169-2174.	3.3	63
11	A single-institution retrospective cohort study of first-line EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. <i>British Journal of Haematology</i> , 2018, 180, 259-266.	1.2	53
12	Epigenetic silencing of miR-708 enhances NF- κ B signaling in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2015, 137, 1352-1361.	2.3	52
13	Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 1884-1888.	0.8	49
14	Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. <i>Journal of Immunology</i> , 2017, 198, 2500-2512.	0.4	43
15	Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4322-4327.	3.3	38
16	Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. <i>Leukemia and Lymphoma</i> , 2020, 61, 387-396.	0.6	29
17	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	0.6	27
18	Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. <i>Blood</i> , 2016, 128, 1215-1215.	0.6	25

#	ARTICLE	IF	CITATIONS
19	The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 25942-25954.	0.8	23
20	Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008777.	1.3	22
21	Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 639-639.	0.6	22
22	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1.	0.2	19
23	Proteomic profiling identifies specific histone species associated with leukemic and cancer cells. <i>Clinical Proteomics</i> , 2015, 12, 22.	1.1	18
24	Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. <i>International Journal of Cancer</i> , 2017, 140, 1899-1906.	2.3	15
25	Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701. <i>Blood</i> , 2021, 138, 523-523.	0.6	14
26	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	3.3	12
27	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10.	0.6	12
28	A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1025-1029.	0.4	11
29	Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1993-2001.	2.0	10
30	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2951-2951.	0.6	10
31	Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 28684-28696.	0.8	9
32	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207.	1.2	8
33	Overall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 40-50.	0.5	6
34	Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). <i>Blood</i> , 2018, 132, 146-146.	0.6	6
35	Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 3983-3983.	0.6	5
36	A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 766-774.	0.2	4

#	ARTICLE	IF	CITATIONS
37	Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 968-968.	0.6	4
38	Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8042-8042.	0.8	4
39	Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1005-1012.	1.1	3
40	Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7544-7544.	0.8	3
41	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 6338.	5.8	3
42	Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia</i> , 2022, 36, 2129-2131.	3.3	3
43	Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 1589-1597.	0.6	2
44	The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2911-2911.	0.6	2
45	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2953-2953.	0.6	2
46	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. <i>Blood</i> , 2016, 128, 4388-4388.	0.6	2
47	Depth of response and progression free survival in CLL patients on ibrutinib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7514-7514.	0.8	2
48	Second cancer incidence in CLL patients receiving BTK inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7511-7511.	0.8	2
49	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Blood</i> , 2020, 136, 2-3.	0.6	1
50	Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2436-2436.	0.6	1
51	Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7528-7528.	0.8	1
52	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 22-23.	0.6	1
53	A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 27-30.	0.6	1
54	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2021, 35, 3287-3290.	3.3	0

#	ARTICLE	IF	CITATIONS
55	Utilization of EBV DNA Copy Number Monitoring in Extranodal NK Lymphoma, Nasal Type in Non Asian Patients. <i>Blood</i> , 2012, 120, 5088-5088.	0.6	0
56	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. <i>Blood</i> , 2012, 120, 3865-3865.	0.6	0
57	Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). <i>Blood</i> , 2015, 126, 4328-4328.	0.6	0
58	A Retrospective Study of Clinical and Laboratory Characteristics in Patients Diagnosed with Platelet Storage Pool Deficiency. <i>Blood</i> , 2018, 132, 1148-1148.	0.6	0
59	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. <i>Blood</i> , 2018, 132, 2878-2878.	0.6	0
60	Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD). , 2019, 2, 079-082.		0
61	Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20004-e20004.	0.8	0
62	Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status. <i>Blood</i> , 2021, 138, 1563-1563.	0.6	0
63	Strategies to Account for Design Misspecifications in Randomized Controlled Trials. , 2022, 1, .		0